BioSpectrum Asia - January 2023

この問題で

Life Sciences Trends to Watch for in 2023
The past two years have been a rollercoaster ride for the global economy and the pharma industry hasn’t been impervious to the major financial upheavals either. Yes, it’s the Pandemic and Post-Pandemic world that’s been influencing people from all walks of life and industries, alike. Buzzwords notwithstanding, we do have to thank the pandemic situation that forced all stakeholders to innovate and pool the best and brightest resources to keep the Life Sciences industry thriving. While all other industries either lost steam in their growth plans, pharma boomed, not unlike the Phoenix rising from the ashes. It is this streak of resilience and growth that we want industry insiders to comment on. With curtains down for 2022, it’s time to look to the new year without the trepidation of the looming ‘Great Reset’. On an upbeat note, BioSpectrum brings you 23 trends and projections for 2023 that could reshape and influence our collective future.

Japan approves manufacturing and marketing of Adtralza for atopic dermatitis

Denmark-based LEO Pharma A/S, a global leader in medical dermatology, has announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted approval for the manufacturing and marketing of Adtralza (tralokinumab) subcutaneous injection

1 min

Korea, Singapore strengthen bilateral cooperation over digital health medical devices

South Korean Ministry of Food and Drug Safety (MFDS) recently held a bilateral meeting with the Health Sciences Authority (HSA) of Singapore at Seoul to support the advancement of domestic medical devices into the global market and strengthen bilateral cooperation in the field of digital health medical devices

1 min

Singapore injects

1M into Global Fund for fighting AIDS, malaria and TB

1 min

New Zealand explores

ways to improve clinical trials

1 min

Vaxxas raises A$34M to clinicall advance needle-free vaccines

Vaxxas has completed a financing round which raised 23 million A$34 million) in new funds.

1 min

Merck, Kelun-Biotech ink $9.3B licensing pact for 7 cancer candidates in China

news about finance

1 min

Alliance Pharma unveils state-of-the-art

bioanalytical lab in Brisbane

1 min

Pharmaniaga strives to develop children’s hexavalent vaccine by 2023

Pharmaniaga LifeScience Sdn Bhd PLS), a wholly-owned subsidiary of Malaysia’s leading pharmaceutical company

1 min

IVI, ST Pharm exchange MoU,

clinical development of COVID-19 vaccine

1 min

XtalPi joins hands with Singapore’s EDDC

For cancer drug discovery

1 min

Life Sciences Trends To Watch For In 2023

The past two years have been a rollercoaster ride for the global economy and the pharma industry hasn't been impervious to the major financial upheavals either.

10+ mins

HTAs, CGT Set to Rule Life Sciences Industry in 2023

overnments and other payers make decisions ee the context of the broader economic environment. For 2023 we will continue to see the impact of these global economic trends on payer decisions as they increase financial pressure in the APAC region.

4 mins

Too Much Of A Good Thing...

Thinking long term to ensure that huge amounts of vaccines are not wasted, manufacturers need to have a far-sightedness and not just go on a production spree.

6 mins

“Crovalimab could potentially become the first global drug originating from Singapore”

There has been explosive growth in the mid- size molecules and therapeutic antibody market as many cancers, autoimmune diseases, metabolic diseases, and infectious diseases have been successfully treated.

4 mins

‘Innovations that serve a purpose, paired with a good go-to-market Strategy are attractive for VCs"

Singapore’s health and biomedical landscape constitutes a vibrant pool of innovative medical technology, biotechnology and biopharmaceutical entrepreneurship.

5 mins

“Our ambition requires us to take long-term view, investing in scale and building unmatched capabilities”

The novel trend in single-cell analysis is revolutionising biological research, unravelling underlying genetic credentials while creating new therapeutic approaches and personalised treatments.

5 mins

“We are seeing activity within biotherapeutics market in Southeast Asia’

Jason Neo, Director, Marketing J-KOSEA, SCIEX, Singapore

2 mins

Propelling Genomic Research with Future-Proof Digital Infrastructure

Digital transformation in healthcare has been D at breakneck speed since the outbreak of the COVID-109.

4 mins

Al: Tremendous Potential to Transform Bioprocessing Efficiencies

The biopharmaceutical industry is witnessing unprecedented growth, with a surge in demand for vaccines, monoclonal antibodies mAbs), and advanced modalities including RNA therapeutics, mRNA vaccines, and cell and gene therapies CGTs).

5 mins

Broad-impact Tech Against AMR Threat

According to one of the most comprehensive studies of antimicrobial resistance AMR), 95 million deaths were associated with including 1.27 million deaths attributed to bacterial AMR in 20109.

4 mins

NTU Singapore and Imperial College London strengthen ties

Building on their successful collaboration in setting up the Lee Kong Chian School of Medicine LKCMedicine), Nanyang Technological University, Singapore NTU Singapore) and Imperial College London have signed a new strategic university-wide partnership to expand their scope of collaboration across research, education, and innovation and enterprise.

1 min

One Health Trust BITS Pilani offer PhD

programme in Data Sciences for global health

1 min

AstraZeneca India

appoints Dr Sanjeev Panchal as Country President MD

1 min

Australian first research

trial to explore use of psychedelics for alcohol use disorder

1 min

Thailand develops

speech recognition AI tech for screening depression

1 min

Prejex joins hands with Polybond to make needle-less injections in India

Prejex Inc., a spin-off of Germany-based Prejex GMBH, has entered into an agreement with Polybond, headed by Adit Rathi of Rathi Group to manufacture needleless injections.

1 min

BioSpectrum Asia の記事をすべて読む

BioSpectrum Asia Magazine Description:

BioSpectrum Asia Magazine is a monthly magazine published by MM Activ Sci-Tech Communication in India. It is a leading biotechnology magazine in Asia, covering a wide range of topics related to the biotechnology industry, including:

* Biotechnology news and trends: BioSpectrum Asia covers the latest biotechnology news and trends from India and around the world.
* Biotechnology company profiles and interviews: The magazine profiles leading biotechnology companies in Asia and interviews their CEOs and other top executives.
* Biotechnology research and development: BioSpectrum Asia covers the latest biotechnology research and development from academic institutions and pharmaceutical companies.
* Biotechnology product reviews: The magazine reviews the latest biotechnology products and services.
* Biotechnology industry events: BioSpectrum Asia covers biotechnology industry events from around the world.

BioSpectrum Asia Magazine is a must-read for anyone who wants to stay informed about the latest advances in biotechnology and their potential to impact the world around us.